BMY
43
3
CMS
58
7
MAR
32
-3
PEP
63
4
MET
43
-8
PNW
69
6
RF
48
3
SYK
44
4
RHI
33
3
PPG
53
4
GIS
75
6
FE
57
4
SYY
43
-7
LRCX
49
-6
CAG
72
2
KR
56
3
FOXA
34
-3
DUK
39
5
F
39
3
MCD
67
2
BMY
43
3
CMS
58
7
MAR
32
-3
PEP
63
4
MET
43
-8
PNW
69
6
RF
48
3
SYK
44
4
RHI
33
3
PPG
53
4
GIS
75
6
FE
57
4
SYY
43
-7
LRCX
49
-6
CAG
72
2
KR
56
3
FOXA
34
-3
DUK
39
5
F
39
3
MCD
67
2
Financhill
Back

Mirati Therapeutics 10K Form

Sell
13

MRTX
Mirati Therapeutics

Last Price:
39.07
Seasonality Move:
-0.64%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive MRTX News And Ratings

See the #1 stock for the next 7 days that we like better than MRTX

MRTX Financial Statistics

Sales & Book Value

Annual Sales: $12.44M
Cash Flow: $-129.61M
Price / Cash Flow: 0
Annual Sales: $17.22
Price / Book: 2.28

Profitability

EPS (TTM): -13.18000
Net Income (TTM): $-741.78M
Gross Margin: $11.84M
Return on Equity: -63.03%
Return on Assets: -54.58%

Mirati Therapeutics Earnings Forecast

Key Mirati Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 13 years for MRTX is 95.18%.
  • The Selling, General & Administrative Expenses for MRTX have been equal to 1,927.65% of Gross Profit Margin.
  • The Research & Development expenses have been 4,273.55% of Revenue.
  • The Interest Expense is -0.28% of Operating Income.
  • The Net Earning history of MRTX is -5,955.55% of Total Revenues.
  • Per Share Earnings over the last 20 years have been positive in 6 years.

Mirati Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Healthcare
Current Symbol: MRTX
CUSIP: 60468T
Website: mirati.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 6.96
Quick Ratio: 6.84

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

MRTX Technical Analysis vs Fundamental Analysis

Sell
13
Mirati Therapeutics (MRTX) is a Sell

Is Mirati Therapeutics a Buy or a Sell?